Literature DB >> 23294003

gp130 activation is regulated by D2-D3 interdomain connectivity.

Antje Schütt1, Martin Zacharias, Nico Schneider, Silke Horn, Joachim Grötzinger, Stefan Rose-John, Dirk Schmidt-Arras.   

Abstract

Activation of the IL-6 (interleukin 6) receptor subunit gp130 (glycoprotein 130) has been linked to the formation of complexes with IL-6 and the IL-6 receptor, as well as to gp130 dimerization. However, it has been shown that gp130 is present as a pre-formed dimer, indicating that its activation is not solely dependent on dimerization. Therefore the detailed mechanism of gp130 activation still remains to be deciphered. Recently, deletion mutations of gp130 have been found in inflammatory hepatocellular adenoma. The mutations clustered around one IL-6-binding epitope of gp130 and resulted in a ligand-independent constitutively active gp130. We therefore hypothesized that conformational changes of this particular IL-6-binding epitope precedes gp130 activation. Using a rational structure-based approach we identified for the first time amino acids critical for gp130 activation. We can show that gp130 D2-D3 interdomain connectivity by hydrophobic residues stabilizes inactive gp130 conformation. Conformational destabilization of the EF loop present in domain D2 and disruption of D2-D3 hydrophobic interactions resulted in ligand-independent gp130 activation. Furthermore we show that the N-terminal amino acid residues of domain D1 participate in the activation of the gp130 deletion mutants. Taken together we present novel insights into the molecular basis of the activation of a cytokine receptor signalling subunit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23294003     DOI: 10.1042/BJ20121660

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  6 in total

1.  Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.

Authors:  Karine Poussin; Camilla Pilati; Gabrielle Couchy; Julien Calderaro; Paulette Bioulac-Sage; Yannick Bacq; Valérie Paradis; Emmanuelle Leteurtre; Nathalie Sturm; Jeanne Ramos; Catherine Guettier; Armelle Bardier-Dupas; Anais Boulai; Dominique Wendum; Janick Selves; Tina Izard; Jean-Charles Nault; Jessica Zucman-Rossi
Journal:  Oncoimmunology       Date:  2014-01-03       Impact factor: 8.110

Review 2.  JAK2 activation by growth hormone and other cytokines.

Authors:  Michael J Waters; Andrew J Brooks
Journal:  Biochem J       Date:  2015-02-15       Impact factor: 3.857

3.  Impact of Single Nucleotide Polymorphism in the ANKRD55 Gene on Occurrence and Clinical Characteristics of Rheumatoid Arthritis.

Authors:  Rasoul Salehi; Mina Motaghi; Amirhossein Salehi; Hadi Karimzadeh; Bahram Pakzad
Journal:  Avicenna J Med Biotechnol       Date:  2022 Jul-Sep

Review 4.  Endosomes as Signaling Platforms for IL-6 Family Cytokine Receptors.

Authors:  Dirk Schmidt-Arras; Stefan Rose-John
Journal:  Front Cell Dev Biol       Date:  2021-06-01

5.  Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.

Authors:  Samadhi Aparicio-Siegmund; Jan Sommer; Niloufar Monhasery; Ralf Schwanbeck; Eric Keil; David Finkenstädt; Klaus Pfeffer; Stefan Rose-John; Jürgen Scheller; Christoph Garbers
Journal:  Oncotarget       Date:  2014-04-30

Review 6.  Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11.

Authors:  Riley D Metcalfe; Tracy L Putoczki; Michael D W Griffin
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.